GlassScriptPhysician profile
Sarah A Knuettel
NPI 1316428626
$8,781.69
in general payments reported to CMS, 2019-2025
46 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.25 · 2020: $93.00 · 2021: $372 · 2022: $2,600 · 2023: $2,127 · 2024: $1,651 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,619 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,618.93 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,159.65 | 2021-2025 | |
| Novo Nordisk INC | $1,026.03 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $781.46 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $514.70 | 2021-2025 | |
| Alkermes, INC. | $397.87 | 2022-2025 | Lybalvi, Aristada |
| Astrazeneca Pharmaceuticals LP | $367.47 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $362.87 | 2021-2025 | Trintellix |
| Astellas Pharma US INC | $302.95 | 2023-2025 | Veozah |
| Esperion Therapeutics, INC. | $293.66 | 2020-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $272.63 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $252.19 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.22 | 2020-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $237.51 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $233.89 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.45 | 2020-2024 | Jardiance |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $194.10 | 2023-2025 | |
| Axsome Therapeutics, INC. | $192.87 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $172.65 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $171.35 | 2023-2025 | Gemtesa |
| Evoke Pharma, INC. | $160.50 | 2023-2025 | Gimoti |
| Amgen INC. | $154.37 | 2021-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $144.33 | 2021-2024 | Xarelto |
| Lundbeck LLC | $108.08 | 2023-2025 | Rexulti |
| Ardelyx, INC. | $104.27 | 2024-2025 | Ibsrela |
| Dexcom, INC. | $100.71 | 2023-2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $67.20 | 2023-2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $63.86 | 2020-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $55.38 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $45.57 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $39.97 | 2022 | |
| Viatris Specialty LLC | $39.40 | 2025 | Yupelri |
| Vanda Pharmaceuticals INC. | $35.53 | 2025 | Fanapt, Hetlioz |
| Exact Sciences Corporation | $34.91 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $28.38 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Aimmune Therapeutics, INC. | $22.41 | 2025 | Zenpep |
| Tandem Diabetes Care, INC. | $21.02 | 2022 | |
| Amarin Pharma, INC. | $19.96 | 2021 | |
| Insulet Corporation | $19.95 | 2024 | Omnipod |
| Ironwood Pharmaceuticals, INC | $16.83 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.65 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.74 | 2023 | Horizant |
| Kci USA, INC. | $13.25 | 2019 | |
| Currax Pharmaceuticals LLC | $13.01 | 2022 | |
| Therapeuticsmd, INC. | $12.75 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Knuettel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.